What we are studying
Stage IV Non Small Cell Lung Cancer has been treated with chemotherapy, chemotherapy with antibodies, or a combination of chemotherapy historically. Depending on the stage and other characteristics of your lung cancer, this treatment plan may include surgery, chemotherapy, radiation, or a combination of these therapies.
The purpose of this study is to determine if the administration of standard platinum-based chemotherapy before pembrolizumab, in patients with stage IV non – small cell lung cancer (NSCLC) who have not previously been treated with chemotherapy (chemotherapy naïve), will improve the overall response rate (ORR) compared to pembrolizumab administered before or concurrently with chemotherapy. Pembrolizumab is an antibody designed to block receptors that inhibit the antitumor immune response. By blocking the inhibitory pathway, pembrolizumab allows the immune system to target cancer cells. We are still learning about methods of treatment that are less harmful to individuals. We hope to learn more about safe and effective treatment in this study.